echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qianjin Pharmaceutical Co., Ltd. Valsartan tablets obtained drug registration certificate and regarded as over-evaluated

    Qianjin Pharmaceutical Co., Ltd. Valsartan tablets obtained drug registration certificate and regarded as over-evaluated

    • Last Update: 2021-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 24th, Qianjin Pharmaceutical announced that its subsidiary Qianjin Xiangjiang Pharmaceutical received the "Drug Registration Certificate" for valsartan tablets approved by the State Food and Drug Administration.


    Valsartan tablets are an angiotensin II receptor blocker developed by Novartis, Switzerland, and are mainly used for mild to moderate essential hypertension


    Up to now, the company has invested approximately RMB 10.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.